Healthcare Industry News: linear accelerator
News Release - February 9, 2007
Integra LifeSciences Adds PET Imaging to Its Cancer Fighting XKnife SystemPLAINSBORO, N.J., Feb. 9, 2007 (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that its subsidiary, Integra Radionics, released its latest image registration software, ImageFusion(TM) 3. The software was originally developed in collaboration with Brigham and Women's Hospital in Boston, Massachusetts and the University of Leuven in Belgium, for the precise registration of computed tomography (CT) and magnetic resonance (MR) images. The new version adds the ability to register positron emission tomography (PET) images, which are increasingly used to detect unusual metabolic activity indicative of an active growing tumor. ImageFusion(TM) 3 is also fully automatic, providing image registration in seconds without any manual input or adjustments.
``The ability to fuse PET images will allow us to see more of the tumor and improve our targeting of cancer in the brain and body,'' said Dr. Alirezza Kassaee, PhD, clinical associate professor of radiation oncology at the University of Pennsylvania. ``I'm also very impressed with the new software's speed and accuracy.''
When the ImageFusion(TM) 3 software is used with Integra's XKnife(TM) radiosurgery system, tumors throughout the body can be accurately targeted and precisely treated using focused radiation beams from a linear accelerator. Unlike conventional surgery, XKnife radiosurgery is completely non-invasive and does not require a surgical incision, thus eliminating the discomfort and possible complications associated with standard surgery. Surrounding normal tissue is spared and patients are typically able to leave the hospital immediately after their one-time thirty minute treatment. To date over 45,000 patients have undergone XKnife radiosurgery.
ImageFusion(TM) 3's increased speed is also beneficial when used in conjunction with the OmniSight(TM) image-guided system platform for the treatment of movement disorders. Worldwide prevalence of movement disorders is estimated at over four million people, and demand is increasing for effective therapies to delay disease progression and improve the quality of life for patients. When medication is ineffective, severe movement disorders may respond to deep brain stimulation (DBS). DBS requires precisely located implantable electrodes within the brain, which deliver electrical impulses to counteract the tremors. ImageFusion(TM) 3 software enables neurosurgeons to fuse high definition MR images with precision CT images and obtain exact coordinates for placement of the electrode.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (http://www.Integra-LS.com).
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the ImageFusion(TM) 3, XKnife(TM) radiosurgery system, and the OmniSight(TM) image-guided system platform. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.